Bronchiectasis: A guide for primary care

Australian Family Physician

Volumn 41, Issue 11, 2012, Pages 842-850

  Maguire, Graeme ^a,b  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^b JAMES COOK UNIVERSITY   (Australia)

Author keywords

Anti infective agents; Bronchiectasis; Expectorants; Primary health care; Tomography; X ray computed

Indexed keywords

ANTIINFECTIVE AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID;

AGED; ARTICLE; BRONCHIECTASIS; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; HUMAN; OXYGEN THERAPY; PRIMARY HEALTH CARE; RADIOGRAPHY; SPIROMETRY;

ADRENAL CORTEX HORMONES; ADRENERGIC BETA-AGONISTS; AGED; ANTI-INFECTIVE AGENTS; BRONCHIECTASIS; CHOLINERGIC ANTAGONISTS; FEMALE; HUMANS; OXYGEN INHALATION THERAPY; PRIMARY HEALTH CARE; SPIROMETRY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84871114516     PISSN: 03008495     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. King PT, Holdsworth SR, Farmer M, Freezer N, Villanueva E, Holmes PW. Phenotypes of adult bronchiectasis: onset of productive cough in childhood and adulthood. COPD 2009;6:130-6.
2. Kapur N, Masters IB, Chang AB. Longitudinal growth and lung function in pediatric non-cystic fibrosis bronchiectasis: what influences lung function stability? Chest 2010;138:158-64.
3. Chang AB, Grimwood K, Mulholland EK, Torzillo PJ. Bronchiectasis in Indigenous children in remote Australian communities. Med J Aust 2002;177:200-4.
4. Weycker D, Edelsberg J, Oster G, Tino G. Prevalence and economic burden of bronchiectasis Clin Pulm Med 2005;12:205-9.
5. Seitz AE, Olivier KN, Steiner CA, Montes de Oca R, Holland SM, Prevots DR. Trends and burden of bronchiectasis-associated hospitalizations in the United States, 1993-2006. Chest 2010;138:944-9.
6. King PT, Holdsworth SR, Freezer NJ, Villanueva E, Gallagher M, Holmes PW. Outcome in adult bronchiectasis. COPD 2005;2:27-34.
7. Chang AB, Bell SC, Byrnes CA, et al. Chronic suppurative lung disease and bronchiectasis in children and adults in Australia and New Zealand. Med J Aust 2010;193:356-65.
8. Patel IS, Vlahos I, Wilkinson TM, et al. Bronchiectasis, exacerbation indices, and inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004;170:400-7.
9. Martinez-Garcia MA, Soler-Cataluna JJ, Donat Sanz Y, et al. Factors associated with bronchiectasis in patients with COPD. Chest 2011;140:1130-7.
10. Kim JS, Muller NL, Park CS, et al. Bronchoarterial ratio on thin section CT: comparison between high altitude and sea level. J Comput Assist Tomogr 1997;21:306-11.
11. Matsuoka S, Uchiyama K, Shima H, Ueno N, Oish S, Nojiri Y. Bronchoarterial ratio and bronchial wall thickness on high-resolution CT in asymptomatic subjects: correlation with age and smoking. AJR Am J Roentgenol 2003;180:513-8.
12. Phillips MS, Williams MP, Flower CD. How useful is computed tomography in the diagnosis and assessment of bronchiectasis? Clin Radiol 1986;37:321-5.
13. Grenier P, Maurice F, Musset D, Menu Y, Nahum H. Bronchiectasis: assesscomplicatedment by thin-section CT. Radiology 1986;161:95-9.
14. Tubiana M, Feinendegen LE, Yang C, Kaminski JM. The linear no-threshold relationship is inconsistent with radiation biologic and experimental data. Radiology 2009;251:13-22.
15. Hall EJ, Brenner DJ. Cancer risks from diagnostic radiology. Br J Radiol 2008;81:362-78.
16. Copley SJ. Application of computed tomography in childhood respiratory infections. Br Med Bull 2002;61:263-79.
17. McKenzie D, Frith P, Burdon J, Town G. The COPDX Plan: Australian and New Zealand Guidelines for the management of Chronic Obstructive Pulmonary Disease 2003. Med J Aust 2003;178:S1-40.
18. Cole PJ. Inflammation: a two-edged sword - the model of bronchiectasis. Eur J Respir Dis Suppl 1986;147:6-15.
19. Wurzel D, Marchant JM, Yerkovich ST, Upham JW, Masters IB, Chang AB. Short courses of antibiotics for children and adults with bronchiectasis. Cochrane Database Syst Rev 2011:CD008695.
20. Evans DJ, Bara AI, Greenstone M. Prolonged antibiotics for purulent bronchiectasis in children and adults. Cochrane Database Syst Rev 2007:CD001392.
21. Serisier DJ, Martin ML. Long-term, low-dose erythromycin in bronchiectasis subjects with frequent infective exacerbations. Respir Med 2011;105:946-9.
22. Anwar GA, Bourke SC, Afolabi G, Middleton P, Ward C, Rutherford RM. Effects of long-term low-dose azithromycin in patients with non-CF bronchiectasis. Respir Med 2008;102:1494-6.
23. Frederiksen B, Lanng S, Koch C, Hoiby N. Improved survival in the Danish center-treated cystic fibrosis patients: results of aggressive treatment. Pediatr Pulmonol 1996;21:153-8.
24. Frederiksen B, Koch C, Hoiby N. Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis. Pediatr Pulmonol 1997;23:330-5.
25. Douglas TA, Brennan S, Gard S, et al. Acquisition and eradication of P. aeruginosa in young children with cystic fibrosis. Eur Respir J 2009;33:305-11.
26. Gibson RL, Emerson J, Mayer-Hamblett N, et al. Duration of treatment effect after tobramycin solution for inhalation in young children with cystic fibrosis. Pediatr Pulmonol 2007;42:610-23.
27. Marchetti F, Giglio L, Candusso M, Faraguna D, Assael BM. Early antibiotic treatment of pseudomonas aeruginosa colonisation in cystic fibrosis: a critical review of the literature. Eur J Clin Pharmacol 2004;60:67-74.
28. Troxler RB, Hoover WC, Britton LJ, Gerwin AM, Rowe SM. Clearance of initial mucoid Pseudomonas aeruginosa in patients with cystic fibrosis. Pediatr Pulmonol 2012; doi: 10.1002/ppul.22543. [Epub ahead of print].
29. Pasteur MC, Bilton D, Hill AT. British Thoracic Society guideline for non-CF bronchiectasis. Thorax 2010;65(Suppl 1):i1-58.
30. Griffith DE, Aksamit T, Brown-Elliott BA, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007;175:367-416.
31. Dhillon SS, Watanakunakorn C. Lady Windermere syndrome: middle lobe bronchiectasis and Mycobacterium avium complex infection due to voluntary cough suppression. Clin Infect Dis 2000;30:572-5.
32. Reich JM, Johnson RE. Mycobacterium avium complex pulmonary disease presenting as an isolated lingular or middle lobe pattern. The Lady Windermere syndrome. Chest 1992;101:1605-9.
33. Kapur N, Bell S, Kolbe J, Chang AB. Inhaled steroids for bronchiectasis. Cochrane Database Syst Rev 2009:CD000996.
34. Martinez-Garcia MA, Soler-Cataluna JJ, Perpina-Tordera M, Roman-Sanchez P, Soriano J. Factors associated with lung function decline in adult patients with stable non-cystic fibrosis bronchiectasis. Chest 2007;132:1565-72.
35. Murray MP, Govan JR, Doherty CJ, et al. A randomized controlled trial of nebulized gentamicin in non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med 2011;183:491-9.
36. O'Donnell AE, Barker AF, Ilowite JS, Fick RB. Treatment of idiopathic bronchiectasis with aerosolized recombinant human DNase I. rhDNase Study Group. Chest 1998;113:1329-34.
37. Teper A, Jaques A, Charlton B. Inhaled mannitol in patients with cystic fibrosis: A randomised open-label dose response trial. J Cyst Fibros 2011;10:1-8.
38. Gjoerup J, Hilberg O, Bendstrup E. Inhaled mannitol in the treatment of non-cystic fibrosis bronchiectasis in adults. Respirology 2012;17:927-32.
39. Kellett F, Robert NM. Nebulised 7% hypertonic saline improves lung function and quality of life in bronchiectasis. Respir Med 2011;105:1831-5.
40. Nicolson CH, Stirling RG, Borg BM, Button BM, Wilson JW, Holland AE. The long term effect of inhaled hypertonic saline 6% in non-cystic fibrosis bronchiectasis. Respir Med 2012;106:661-7.
41. Department of Health and Ageing, Australian Government. Immunise Australia Program. 2012. Available at www.immunise.health.gov.au [Accessed 22 July 2012].
42. Murray MP, Pentland JL, Hill AT. A randomised crossover trial of chest physiotherapy in non-cystic fibrosis bronchiectasis. Eur Respir J 2009;34:1086-92.
43. Indinnimeo L, Tancredi G, Barreto M, et al. Effects of a program of hospitalsupervised chest physical therapy on lung function tests in children with chronic respiratory disease: 1-year follow-up. Int J Immunopathol Pharmacol 2007;20:841-5.
44. Newall C, Stockley RA, Hill SL. Exercise training and inspiratory muscle training in patients with bronchiectasis. Thorax 2005;60:943-8.
45. Liaw MY, Wang YH, Tsai YC, et al. Inspiratory muscle training in bronchiectasis patients: a prospective randomized controlled study. Clin Rehabil 2011;25:524-36.
46. Crockett AJ, Cranston JM, Moss JR, Alpers JH. Domiciliary oxygen for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2000;CD001744.
47. McDonald CF, Crockett AJ, Young IH. Adult domiciliary oxygen therapy. Position statement of the Thoracic Society of Australia and New Zealand. Med J Aust 2005;182:621-6.
48. Yu JA, Pomerantz M, Bishop A, Weyant MJ, Mitchell JD. Lady Windermere revisited: treatment with thoracoscopic lobectomy/segmentectomy for right middle lobe and lingular bronchiectasis associated with non-tuberculous mycobacterial disease. Eur J Cardiothorac Surg 2011;40:671-5.
49. Hiramatsu M, Shiraishi Y, Nakajima Y, et al. Risk factors that affect the surgical outcome in the management of focal bronchiectasis in a developed country. Ann Thorac Surg 2012;93:245-50.
50. Mauchley DC, Daley CL, Iseman MD, Mitchell JD. Pulmonary resection and lung transplantation for bronchiectasis. Clin Chest Med 2012;33:387-96.
51. Goeminne PC, Scheers H, Decraene A, Seys S, Dupont LJ. Risk factors for morbidity and death in non-cystic fibrosis bronchiectasis: a retrospective cross-sectional analysis of CT diagnosed bronchiectatic patients. Respir Res 2012;13:21.
52. Chang AB, Grimwood K, Maguire G, King PT, Morris PS, Torzillo PJ. Management of bronchiectasis and chronic suppurative lung disease in indigenous children and adults from rural and remote Australian communities. Med J Aust 2008;189:386-93.
53. Einsiedel L, Fernandes L, Spelman T, Steinfort D, Gotuzzo E. Bronchiectasis is associated with human T-lymphotropic virus 1 infection in an Indigenous Australian population. Clin Infect Dis 2012;54:43-50.